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Chronic inﬂammation is involved in the pathogenesis of insulin resistance, atherosclerosis, neurodegeneration, and tumour
growth. Regular exercise oﬀers protection against type 2 diabetes, cardiovascular diseases, colon cancer, breast cancer, and
dementia. Evidence suggests that the protective eﬀect of exercise may to some extent be ascribed to the antiinﬂammatory eﬀect of
regular exercise. Here we suggest that exercise may exert its anti-inﬂammatory eﬀect via a reduction in visceral fat mass and/or by
induction of an anti-inﬂammatory environment with each bout of exercise. According to our theory, such eﬀects may in part be
mediated via muscle-derived peptides, so-called “myokines”. Contracting skeletal muscles release myokines with endocrine eﬀects,
mediating direct anti-inﬂammatory eﬀects, and/or speciﬁc eﬀects on visceral fat. Other myokines work locally within the muscle
and exert their eﬀects on signalling pathways involved in fat oxidation and glucose uptake. By mediating anti-inﬂammatory eﬀects
inthemuscleitself,myokinesmayalsocounteractTNF-driveninsulinresistance.Inconclusion,exercise-inducedmyokinesappear
to be involved in mediating both systemic as well as local anti-inﬂammatory eﬀects.
1.Introduction
Over the past several decades, numerous large cohort studies
have attempted to quantify the protective eﬀect of physical
activity on cardiovascular and all-cause mortality. A recent
meta-analysis included a total of 33 studies with 883,372
participantswithafollowuptimeofuptomorethan20years
[1]. Concerning cardiovascular mortality, physical activity
was associated with a risk reduction of 35%, whereas all-
cause mortality was reduced by 33%. Taken together, there
is no doubt that physical activity is independently associated
with a marked decrease in risk of cardiovascular disease
(CVD) as well as CVD mortality in both men and women.
Randomised controlled trials including people with
impaired glucose tolerance have found that lifestyle mod-
iﬁcation (diet and moderate physical activity) protects
against the development of type 2 diabetes. A Finnish
trial randomised 522 overweight middle-aged people with
impaired glucose tolerance to physical training combined
with diet or to control and followed them for 3.2 years
[2]. The risk of type 2 diabetes was reduced by 58% in the
intervention group. Theeﬀectwaslargestinthepatientswho
made the greatest lifestyle modiﬁcation. An American trial
randomised 3,234 people with impaired glucose tolerance
to treatment with metformin, lifestyle modiﬁcation entailing
dietary change and at least 150 minutes of physical exercise
weekly, or placebo and followed them for 2.8 years [3]. The
lifestyle modiﬁcation reduced the risk of type 2 diabetes by
58%. The reduction was, thus, the same as in the Finnish
trial [2], whereas treatment with metformin only reduced
the risk of diabetes by 31%. After a median of 4 years of
active intervention period, participants in the Finnish study
who were still free of diabetes were further followed up for a
median of 3 years. During the total followup, the incidence
of type 2 diabetes was 4.3 and 7.4 per 100 person-years in
the intervention and control groups, respectively, indicating
43% reduction in relative risk. The risk reduction was related
to the success in achieving the intervention goals of weight
loss, reduced intake of total and saturated fat and increased
intake of dietary ﬁbre, and increased physical activity [4].2 Journal of Biomedicine and Biotechnology
In humans, type 2 diabetes are associated with impaired
cognitive function, including learning, memory, and pro-
cessing speed [5]. Large longitudinal population-based stud-
ies show that the rate of cognitive decline is accelerated in
elderly people with type 2 diabetes [6]. A recent review [7]
showed that the incidence of ‘any dementia’ was higher in
individuals with type 2 diabetes than in those without. This
high risk included both Alzheimer’s disease and vascular
dementia. Interestingly, a couple of studies suggest that
regular exercise also protects against dementia [8–10].
Type 2 diabetes, cardiovascular diseases, colon cancer,
breast cancer, and dementia constitute a cluster of diseases
that deﬁnes “a diseasome of physical inactivity” [11].
Both physical inactivity and abdominal adiposity, reﬂecting
accumulation of visceral fat mass, are associated with the
occurrence of the diseases within the diseasome. We recently
suggested that physical inactivity leads to accumulation of
visceral fat and consequently the activation of a network
of inﬂammatory pathways, which promote the development
of insulin resistance, atherosclerosis, neurodegeneration,
tumour growth, and thereby the development of the diseases
belonging to the “diseasome of physical inactivity” [11].
Chronic inﬂammation accompanies the diseases within
the “diseasome of physical inactivity”, potentially explaining
the clustering of these chronic disorders in epidemiological
studies. The aim of the present review is to summarize the
evidence suggesting that regular exercise creates an anti-
inﬂammatory environment, and thereby oﬀers protection
against a vast number of chronic diseases.
2. Inﬂammation as a Causeof ChronicDiseases
Systemic low-grade inﬂammation is deﬁned as two- to four-
fold elevations in circulating levels of proinﬂammatory and
anti-inﬂammatory cytokines, naturally occurring cytokine
antagonists, and acute-phase proteins, as well as minor
increases in counts of neutrophils and natural killer cells
[12–14]. Chronic inﬂammation contributes to the develop-
ment of atherosclerosis, insulin resistance, tumour growth,
and neurodegenation [15], and thus directly inﬂuences
pathogenesis of key importance for the development of the
chronicdiseaseswithinthe“diseasomeofphysicalinactivity”
[11].
It appears that TNF-α may play a direct role in the
metabolic syndrome, recently reviewed in [16]. In vitro
studies demonstrate that TNF-α has direct inhibitory eﬀects
on insulin signalling. Moreover, TNF-α infusion in healthy
humansinducesinsulinresistanceinskeletalmuscle,without
an eﬀect on endogenous glucose production [17].
It has also been proposed that TNF-α causes insulin
resistance indirectly in vivo by increasing the release of
free fatty acids (FFAs) from adipose tissue. TNF-α increases
lipolysis in human and 3T3-L1 adipocytes. However, TNF-
α has no eﬀect on muscle protein turnover or fatty acid
oxidation but increases fatty acid incorporation into diacyl-
glycerol, which may be involved in the development of the
TNF-α-induced insulin resistance in skeletal muscle [18, 19].
Moreover, evidence suggests that TNF-α plays a direct role in
linking insulin resistance to vascular disease [20, 21]. Several
downstream mediators and signalling pathways seem to
provide the crosstalk between inﬂammatory and metabolic
signalling. These include the discovery of c-Jun N-terminal
kinase (JNK) and I kappa beta kinase (IKK) as critical
regulators of insulin action activated by TNF-α [22]. In
humanTNF-αinfusionstudies,TNF-αincreasesphosphory-
lation of p70 S6 kinase, extracellular signal-regulated kinase-
1/2, and c-Jun NH(2)-terminal kinase, concomitantly with
increased serine and reduced tyrosine phosphorylation of
insulin receptor substrate-1[21]. These signalling eﬀects are
associated with impaired phosphorylation of Akt substrate
160, the most proximal step identiﬁed in the insulin sig-
nalling cascade regulating GLUT4 translocation and glucose
uptake [21].
The role of IL-6 in insulin resistance is highly contro-
versial, as reviewed in [16]. Infusion of recombinant human
(rh)IL-6 into resting healthy humans does not impair whole
body, lower limb, or subcutaneous adipose tissue glucose
uptake or endogenous glucose production (EGP), although
IL-6 contributes to the contraction-induced increase in
endogenous glucose production [16]. A number of studies
indicate that IL-6 enhances lipolysis, as well as fat oxidation,
via an activation of AMP-activated protein kinase (AMPK),
reviewed in [16]. Consistent with this idea, Wallenius et
al. [23] demonstrated that IL-6 deﬁcient mice developed
mature-onset obesity and insulin resistance. In addition,
when the mice were treated with IL-6, there was a signiﬁcant
decrease in body fat mass in the IL-6 knockout, but not
in the wild-type mice. To determine whether physiologi-
cal concentrations of IL-6 aﬀected lipid metabolism, our
group administered physiological concentrations of rhIL-6
to healthy young and elderly humans as well as to patients
with type 2 diabetes [24, 25]. The latter studies identiﬁed
IL-6 as a potent modulator of fat metabolism in humans,
increasing lipolysis as well as fat oxidation without causing
hypertriacylglycerolaemia.
Of note, whereas it is known that both TNF-α and IL-
6 induce lipolysis, only IL-6 appears to induce fat oxidation
[18, 25]. Although circulating levels of TNF-α and IL-6
coexistinepidemiologicalstudies[26],thebiologicalproﬁles
of these cytokines are very diﬀerent. TNF-α stimulates
the release of IL-6 and one theory holds that it is TNF-
α derived from adipose tissue that is actually the major
“driver” behind inﬂammation-induced insulin resistance
and atherosclerosis.
Importantly, also tumour progression is stimulated by
systemic elevation of proinﬂammatory cytokines [15, 27]. In
addition, a number of neurodegenerative diseases are linked
to a local inﬂammatory response in the brain (neuroinﬂam-
mation) and systemic inﬂammation may further exacerbate
the progression of neurodegeneration [28].
In summary, inﬂammation is directly involved in the
pathogenesis of insulin resistance, atherosclerosis, neurode-
generation, and tumour growth. Therefore, the ﬁnding that
type 2 diabetes, cardiovascular diseases, Alzheimer‘s disease
and cancer is associated with chronic inﬂammation suggests
that inﬂammatory mechanisms contribute as causative fac-
tors in the development of these disorders.Journal of Biomedicine and Biotechnology 3
3.The Myokine Concept
The protective eﬀect of exercise against diseases associated
with chronic inﬂammation may to some extent be ascribed
to an anti-inﬂammatory eﬀect of regular exercise.
In line with the acceptance of adipose tissue as an
endocrine organ, we came up with the innovative idea that
also skeletal muscle should be viewed as an endocrine organ.
We have suggested that cytokines and other peptides that
are produced, expressed, and released by muscle ﬁbres and
exert paracrine or endocrine eﬀects should be classiﬁed
as “myokines”. This paradigm provides a conceptual basis
explaining the multiple consequences of a physically inactive
lifestyle. If the endocrine and paracrine functions of the
muscle are not stimulated through contractions, this will
cause dysfunction of several organs and tissues of the body
as well as an increased risk of cardiovascular disease, cancer,
and dementia.
Today, it appears that skeletal muscle has the capacity to
express several myokines. The list includes IL-6, IL-8, IL-
15 [29], BDNF [30], and LIF [31]. In addition, Kenneth
Walsh, Boston, has recently identiﬁed the myokines FGF21
and Follistatin-like-1 [32, 33].
The prototype myokine, IL-6, appears to be able to
mediate metabolic eﬀects as well as anti-inﬂammatory
eﬀects. IL-6 was the ﬁrst identiﬁed and to date most
studied myokine. The gp130 receptor cytokine IL-6 was
discovered as a myokine because of the observation that it
increases up to 100-fold in the circulation during physical
exercise. Identiﬁcation of IL-6 production by skeletal muscle
during physical activity generated renewed interest in the
metabolic role of IL-6 because it created a paradox. On one
hand, IL-6 is markedly produced and released in the post-
exercise period when insulin action is enhanced but, on the
other hand, IL-6 has also been associated with obesity and
reduced insulin action. However, a number of studies during
the past decade have revealed that in response to muscle
contractions both type I and type II muscle ﬁbres express
the myokine IL-6, which subsequently exerts its eﬀects both
locally within the muscle (e.g., through activation of AMPK)
and—when released into the circulation—peripherally in
several organs in a hormone-like fashion. Within skeletal
muscle, IL-6 acts locally to signal through gp130Rβ/IL-
6Rα, resulting in activation of AMPK and/or PI3-kinase to
increase glucose uptake and fat oxidation. IL-6 may also
work in an endocrine fashion to increase hepatic glucose
production during exercise or lipolysis in adipose tissue,
reviewed in [16].
IL-15 is expressed in human skeletal muscle, and has
been identiﬁed as an anabolic factor in muscle growth,
and appears also to play a role in lipid metabolism [34].
Recently, we demonstrated that IL-15 mRNA levels were
upregulated in human skeletal muscle following a bout of
strength training [35], suggesting that IL-15 may accumulate
within the muscle as a consequence of regular training.
Interestingly, a negative association exists between plasma
IL-15 concentration and trunk fat mass. In support of the
human data, we found a decrease in visceral fat mass, but
not subcutaneous fat mass, when IL-15 was overexpressed
in murine muscle [36]. Quinn et al. found that elevated
circulating levels of IL-15 resulted in signiﬁcant reductions
in body fat and increased bone mineral content, without
appreciably aﬀecting lean body mass or levels of other
cytokines [37]. These ﬁndings lend support to the idea that
muscle-expressed IL-15 may be involved in the regulation of
visceral fat mass.
BDNF is recognized as playing a key role in regulating
survival, growth, and maintenance of neurons [38], and
BDNF plays a role in learning and memory [39]. Hippocam-
pal samples from Alzheimer’s disease donors show decreased
BDNF expression [40] and individuals with Alzheimer’s
disease have low plasma levels of BDNF [41]. Also, patients
with major depression have lower levels of serum BDNF
than normal control subjects [42]. Other studies suggest
that plasma BDNF is a biomarker of impaired memory
and general cognitive function in ageing women [43]a n d
a low circulating BDNF level was recently shown to be
an independent and robust biomarker of mortality risk
in old women [44]. Interestingly, we found low levels of
circulating BDNF also in individuals with both obesity and
type 2 diabetes [45]. Thus, BNDF is low in people with
Alzheimer’s disease, major depression, impaired cognitive
function, CVD, type 2 diabetes, and obesity.
We studied whether skeletal muscle would produce
BDNF in response to exercise [46]. It was found that BDNF
mRNAandproteinexpressionwasincreasedinhumanskele-
tal muscle after exercise; however; muscle-derived BDNF
appeared not to be released into the circulation. In addition,
BDNF mRNA and protein expression was increased in
muscle cells that were electrically stimulated. Interestingly,
BDNF increased phosphorylation of AMPK and Acetyl Co-
carboxylase (ACC) and enhanced fat oxidation both in vitro
a n de xv i v o .T h u s ,w eh a v eb e e na b l et oi d e n t i f yB D N Fa sa
novel contraction-induced muscle cell-derived protein that
may increase fat oxidation in skeletal muscle in an AMPK-
dependent fashion. BDNF appears to be a myokine that
worksinanautocrineorparacrinefashionwithstrongeﬀects
on peripheral metabolism, including fat oxidation with a
subsequent eﬀect on the size of adipose tissue [30].
In summary, contracting skeletal muscles release
myokines, which create a systemic anti-inﬂammatory
environment and exert speciﬁc endocrine eﬀects on visceral
fat. Such myokines may also work locally within the muscle
and exert their eﬀects on signalling pathways involved in
fat oxidation and glucose uptake. Taken together, myokines
may be involved in mediating the anti-inﬂammatory eﬀects
of exercise.
4. The Anti-inﬂammatoryEffects of
an Acute Bout of Exercise
Regularexerciseappearstoinduceanti-inﬂammatoryeﬀects,
suggesting that physical activity per se may suppress systemic
low-grade inﬂammation [47]. Several studies show that
markers of inﬂammation are reduced following longer-term
behavioural changes involving both reduced energy intake
and increased physical activity, reviewed in [48]. However,4 Journal of Biomedicine and Biotechnology
the mediators of this eﬀect are unresolved. A number of
mechanisms have been identiﬁed. Exercise increases the
release of epinephrine, cortisol, growth hormone, prolactin,
and other factors that have immunomodulatory eﬀects [15,
49].
IL-6 is the ﬁrst cytokine present in the circulation during
exercise and the appearance of IL-6 in the circulation is
by far the most marked and its appearance precedes that
of the other cytokines. The fact that the classical pro-
inﬂammatory cytokines, TNF-α and IL-1β, in general do
not increase with exercise, whereas exercise provokes an
increase in circulating levels of IL-1ra, IL-10, and sTNF-R
[50, 51], suggests that exercise provokes an environment of
anti-inﬂammatory cytokines. Importantly, we showed that
rhIL-6 infusion as well as exercise inhibited the endotoxin-
induced increase in circulating levels of TNF-α in healthy
humans[52].Theanti-inﬂammatoryeﬀectsofIL-6havealso
beendemonstratedbyIL-6stimulating theproductionofthe
classical anti-inﬂammatory cytokines IL-1ra and IL-10 [53].
Recent work has shown that both upstream and down-
stream signalling pathways for IL-6 diﬀer markedly between
myocytes and macrophages. It appears that unlike IL-
6 signalling in macrophages, which is dependent upon
activation of the NFκB signalling pathway, intramuscular
IL-6 expression is regulated by a network of signalling cas-
cades, including the Ca2+/NFAT and glycogen/p38 MAPK
pathways. Thus, when IL-6 is signalling in monocytes
or macrophages, it creates a pro-inﬂammatory response,
whereas IL-6 activation and signalling in muscle is totally
independent of a preceding TNF-response or NFκBa c t i v a -
tion.
In summary, the possibility exists that with regular
exercise the anti-inﬂammatory eﬀects of an acute bout
of exercise will protect against chronic systemic low-grade
inﬂammation, but such a direct link between the acute
eﬀects of exercise and the long-term beneﬁts has yet to be
established.
5. Conclusion
The authors suggest that the beneﬁcial eﬀects of regular
exercise may be due to the anti-inﬂammatory eﬀects of
muscle contractions. Such exercise eﬀects may be mediated
via long-term eﬀects on abdominal adiposity and/or by the
anti-inﬂammatory environment that is created by each acute
bout of exercise.
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